Geographic and temporal trends in aetiology, incidence and mortality from hepatocellular carcinoma in European Union 15+ countries

Georgina Hanbury, Chinmay Jani, Nour Abdallah, Shoheera Punjwani, Omar Al Omari, Harpreet Singh, Ruchi Jani, Joseph Shalhoub, Justin D. Salciccioli, Dominic C. Marshall, David J. Pinato
{"title":"Geographic and temporal trends in aetiology, incidence and mortality from hepatocellular carcinoma in European Union 15+ countries","authors":"Georgina Hanbury,&nbsp;Chinmay Jani,&nbsp;Nour Abdallah,&nbsp;Shoheera Punjwani,&nbsp;Omar Al Omari,&nbsp;Harpreet Singh,&nbsp;Ruchi Jani,&nbsp;Joseph Shalhoub,&nbsp;Justin D. Salciccioli,&nbsp;Dominic C. Marshall,&nbsp;David J. Pinato","doi":"10.1002/lci2.77","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. This study considers the geographical trends in incidence and mortality from HCC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data were obtained for each EU15+ country from the Global Burden of Disease Study database. Age-standardised incidence rates (ASIRs), mortality rates (ASMRs) and disability-adjusted life years (DALYs) were extracted for each year from 1990 to 2019. Data were subdivided into males and females. Mortality-to-incidence ratios (MIRs) were calculated. All Indices were reported per 100 000 population, and trends were described using Joinpoint regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>ASIRs increased in 17/19 countries in females and 18/19 countries in males between 1990 and 2019. ASMRs increased in all countries except Italy (for both sexes) and Sweden (for females). MIR decreased in all countries except Denmark in males (+8.0) and females (+1.2). Ireland saw the greatest decline in MIR among females (−15.0%) and the United Kingdom for males (−16.4%). DALYs increased in all countries except Italy for males and females and Sweden for females.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The incidence of and mortality from hepatocellular carcinoma are increasing in the majority of EU15+ countries. The rise in mortality and fall in MIR may suggest that outcomes from HCC are improving, despite an increased disease burden.</p>\n </section>\n </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"4 3-4","pages":"109-120"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.77","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver cancer international","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lci2.77","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims

Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. This study considers the geographical trends in incidence and mortality from HCC.

Methods

Data were obtained for each EU15+ country from the Global Burden of Disease Study database. Age-standardised incidence rates (ASIRs), mortality rates (ASMRs) and disability-adjusted life years (DALYs) were extracted for each year from 1990 to 2019. Data were subdivided into males and females. Mortality-to-incidence ratios (MIRs) were calculated. All Indices were reported per 100 000 population, and trends were described using Joinpoint regression.

Results

ASIRs increased in 17/19 countries in females and 18/19 countries in males between 1990 and 2019. ASMRs increased in all countries except Italy (for both sexes) and Sweden (for females). MIR decreased in all countries except Denmark in males (+8.0) and females (+1.2). Ireland saw the greatest decline in MIR among females (−15.0%) and the United Kingdom for males (−16.4%). DALYs increased in all countries except Italy for males and females and Sweden for females.

Conclusions

The incidence of and mortality from hepatocellular carcinoma are increasing in the majority of EU15+ countries. The rise in mortality and fall in MIR may suggest that outcomes from HCC are improving, despite an increased disease burden.

Abstract Image

欧盟 15 个以上国家肝细胞癌的病因、发病率和死亡率的地域和时间趋势
背景和目的 肝细胞癌(HCC)是全球癌症死亡的第三大原因。本研究探讨了 HCC 发病率和死亡率的地域趋势。 方法 从全球疾病负担研究数据库中获取每个欧盟 15+ 国家的数据。提取了 1990 年至 2019 年每年的年龄标准化发病率 (ASIR)、死亡率 (ASMR) 和残疾调整生命年 (DALY)。数据细分为男性和女性。计算了死亡率与发病率的比率(MIRs)。所有指数均以每 10 万人口为单位进行报告,并使用 Joinpoint 回归法描述趋势。 结果 1990 年至 2019 年期间,17/19 个国家的女性和 18/19 个国家的男性的 ASIRs 均有所上升。除意大利(男女)和瑞典(女性)外,所有国家的 ASMRs 都有所增加。除丹麦(+8.0)和丹麦(+1.2)外,所有国家的男性和女性死亡率均有所下降。爱尔兰的女性死亡率下降幅度最大(-15.0%),英国的男性死亡率下降幅度最大(-16.4%)。除意大利(男性和女性)和瑞典(女性)外,所有国家的残疾调整寿命年数都有所增加。 结论 大多数欧盟 15+ 国家的肝细胞癌发病率和死亡率都在上升。死亡率的上升和MIR的下降可能表明,尽管疾病负担加重,但肝细胞癌的治疗效果正在改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信